Publications by authors named "F S Rhame"
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV.
J Acquir Immune Defic Syndr
August 2022
Article Synopsis
- Limited data exists on asymptomatic COVID-19 infections in people with HIV (PWH), but findings from a major global clinical trial reveal that 60% of SARS-CoV-2 infections in PWH are asymptomatic.
- The study involved 2,464 participants, where 13% were found to be infected with SARS-CoV-2, with 40% of those showing symptoms and the majority being asymptomatic.
- PWH with asymptomatic infections tended to be older, from low-income regions, and of Black or African American race, highlighting the importance of ongoing COVID-19 testing in this population.
The objective of this paper is to determine the temporal trend of the association of 66 comorbidities with human immunodeficiency virus (HIV) infection status among Medicare beneficiaries from 2000 through 2016.We harvested patient level encounter claims from a 17-year long 100% sample of Medicare records. We used the chronic conditions warehouse comorbidity flags to determine HIV infection status and presence of comorbidities.
View Article and Find Full Text PDFHIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH).
View Article and Find Full Text PDFBackground: Persistent inflammation and incomplete immune recovery among persons with HIV (PHIV) are associated with increased disease risk. We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis.
Methods: Losartan (100 mg) versus placebo over 12 months was investigated in a randomized (1 : 1) placebo-controlled trial, among PHIV age at least 50 years, receiving antiretroviral therapy (ART), with HIV RNA less than 200 copies/ml and CD4+ cell count 600 cells/μl or less.